The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

CRISPR Therapeutics AG (CRSP) closed at $47.69 in the latest trading session, marking a -4.79% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Elsewhere ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

A vanadium MXene nanoparticle uses gene editing to strip tumors of heat resistance, then kills them with laser-triggered free ...

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...

Neither the Parties nor the Patent Trial and Appeal Board (PTAB) have been resting in addressing the decision by the Federal ...

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital ...

If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...